Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Voriconazole

Voriconazole Reactions 1704, p367 - 2 Jun 2018 Hyperbilirubinaemia: case report In a retrospective study of 200 patients, a patient [age and sex not stated] was described, who developed hyperbilirubinaemia during treatment with voriconazole. The patient, who had neutropenia and haematological malignancies, started receiving anti-fungal prophylaxis with oral voriconazole tablet 200mg twice a day. Subsequently, the patient developed hyperbilirubinaemia, and voriconazole was discontinued [duration of treatment to reaction onset and outcome not stated]. Author comment: "Eleven patients had to discontinue voriconazole. . .hyperbilirubinemia (one patient)". "Symptomatic adverse events were significantly more common in the voriconazole group." Hachem R, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. International Journal of Antimicrobial Agents 50: 384-388, No. 3, Sep 2017. Available from: URL: http://doi.org/10.1016/ j.ijantimicag.2017.03.021 - USA 803324029 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Voriconazole

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Voriconazole

Abstract

Reactions 1704, p367 - 2 Jun 2018 Hyperbilirubinaemia: case report In a retrospective study of 200 patients, a patient [age and sex not stated] was described, who developed hyperbilirubinaemia during treatment with voriconazole. The patient, who had neutropenia and haematological malignancies, started receiving anti-fungal prophylaxis with oral voriconazole tablet 200mg twice a day. Subsequently, the patient developed hyperbilirubinaemia, and voriconazole was discontinued [duration of...
Loading next page...
1
 
/lp/springer-journals/voriconazole-mmsiVNgXaJ

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-47010-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p367 - 2 Jun 2018 Hyperbilirubinaemia: case report In a retrospective study of 200 patients, a patient [age and sex not stated] was described, who developed hyperbilirubinaemia during treatment with voriconazole. The patient, who had neutropenia and haematological malignancies, started receiving anti-fungal prophylaxis with oral voriconazole tablet 200mg twice a day. Subsequently, the patient developed hyperbilirubinaemia, and voriconazole was discontinued [duration of treatment to reaction onset and outcome not stated]. Author comment: "Eleven patients had to discontinue voriconazole. . .hyperbilirubinemia (one patient)". "Symptomatic adverse events were significantly more common in the voriconazole group." Hachem R, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. International Journal of Antimicrobial Agents 50: 384-388, No. 3, Sep 2017. Available from: URL: http://doi.org/10.1016/ j.ijantimicag.2017.03.021 - USA 803324029 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.